<?xml version="1.0" encoding="UTF-8"?>
<p>Pharmaceutical company leaders acknowledged that “depending on the circumstances for the emergency, preliminary data could be made available with clear descriptions of the verifications that are ongoing and the remaining risks to data integrity” [
 <xref rid="pmed.1002109.ref023" ref-type="bibr">23</xref>]. WHO officials noted that research teams generated and exchanged critical data for novel vaccines faster than ever [
 <xref rid="pmed.1002109.ref024" ref-type="bibr">24</xref>].
</p>
